Hematopoiesis has been extensively studied in many animal models, including mouse embryonic stem (ES) cells and murine embryos. However, analyses of human hematopoietic development typically utilize blood cells isolated from bone marrow or umbilical cord blood. While these post-natal human hematopoietic stem cells (HSCs) have been well characterized, considerably less is known about how these HSCs arise from earlier precursor cells during the initial stages of human development. Human ES cells provide an optimal starting point to study fundamental questions of human developmental biology, and to define phenotypic and genetic regulation of rare precursor cells. The overall goal of this proposal is to use human ES cells to systematically characterize human hematopoietic precursor cell development. We have previously demonstrated methods to derive CD34+, CD45+ and mature myeloid-lineage cells from human ES cells. More recently, we have also derived lymphocytes from CD34+ human ES cell-derived precursor cells. While we demonstrate an ordered development of hematopoietic cells derived from human ES cells, more complete understanding of the conditions required for hematopoiesis from human ES cells is still lacking. To better characterize fundamental cellular and molecular mechanisms of early human hematopoiesis, we will do the following. 1) Define soluble and cell bound proteins essential for development of blood cells from human ES cells, with particular emphasis on Wnt proteins. 2) Characterize the phenotype of human ES cell derived HSCs by in vitro surrogate assays and transplantation into immunodeficient mice. 3) Isolate clonal populations of hemangioblast or hemogenic endothelial cells that serve as a common precursor to both blood and endothelial cell lineages. Successful completion of these aims will significantly advance our ability to use human ES cells to understand basic human development, with important applications to better stem-cell based therapies. (These studies will use NIH registry WA01 and WA09 human ES cells). Relevance to public health: These studies will have important impact in the rapidly growing area of regenerative medicine. Better understanding of hematopoietic development from human ES cells will translate to novel source of cells for hematopoietic cell transplants used to treat a variety of malignant and non-malignant blood cell diseases. These cells may also be used as a new source for transfusion medicine.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL077923-05
Application #
7799200
Study Section
Hematopoiesis Study Section (HP)
Program Officer
Thomas, John
Project Start
2006-04-01
Project End
2012-03-31
Budget Start
2010-04-01
Budget End
2012-03-31
Support Year
5
Fiscal Year
2010
Total Cost
$362,911
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Ferrell, Patrick I; Xi, Jiafei; Ma, Chao et al. (2015) The RUNX1 +24 enhancer and P1 promoter identify a unique subpopulation of hematopoietic progenitor cells derived from human pluripotent stem cells. Stem Cells 33:1130-41
Ni, Zhenya; Knorr, David A; Bendzick, Laura et al. (2014) Expression of chimeric receptor CD4? by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells 32:1021-31
Bock, Allison M; Knorr, David; Kaufman, Dan S (2013) Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs). J Vis Exp :e50337
Knorr, David A; Bock, Allison; Brentjens, Renier J et al. (2013) Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy. Stem Cells Dev 22:1861-9
Geller, Melissa A; Knorr, David A; Hermanson, David A et al. (2013) Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy 15:1297-306
Simara, Pavel; Motl, Jason A; Kaufman, Dan S (2013) Pluripotent stem cells and gene therapy. Transl Res 161:284-92
Knorr, David A; Ni, Zhenya; Hermanson, David et al. (2013) Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med 2:274-83
Waldron, Nate N; Oh, Seunguk; Vallera, Daniel A (2012) Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma. Oral Oncol 48:1202-7
Liu, Yang; Wang, Xintong; Kaufman, Dan S et al. (2011) A synthetic substrate to support early mesodermal differentiation of human embryonic stem cells. Biomaterials 32:8058-66
Xiong, Qiang; Hill, Katherine L; Li, Qinglu et al. (2011) A fibrin patch-based enhanced delivery of human embryonic stem cell-derived vascular cell transplantation in a porcine model of postinfarction left ventricular remodeling. Stem Cells 29:367-75

Showing the most recent 10 out of 27 publications